Pursue Your Bullous Pemphigoid Therapy with Worldwide Clinical Trials
Bullous pemphigoid is a rare immune-mediated inflammatory disorder (IMID) that presents as itchy, fluid-filled blisters, usually on the lower abdomen, upper thighs, armpits, or other areas of flexion. In very rare cases, the blisters – or bullae – form on the mucus membranes of the mouth or eyes. No one knows what causes bullous pemphigoid, and the condition often goes away on its own.
Although bullous pemphigoid can resolve itself in less than five years, no one with the condition wants to endure the itching blisters for that amount of time, particularly since most people who develop bullous pemphigoid are more than 60 years old and know how precious five years can be. Corticosteroid medications have been shown to help, but these can take months to quiet the inflammation. Meanwhile, if – or when – the blisters burst, there is an ongoing risk of infection that can be even more dangerous than the condition itself.
Researchers working on therapies to prevent bullous pemphigoid or to lessen the discomfort and/or accelerate the remission of the condition will find receptive patients when their efforts reach the marketplace. But before they do, researchers must prove those therapies to be both safe and effective.
That’s where Worldwide Clinical Trials can help. With more than 30 years of experience supporting IMID research, Worldwide is an internationally acclaimed expert in clinical trial management. We offer full-service support for Phase I-Phase IV clinical trials, as well as real-world evidence studies that can help you understand the effects of your work over both the short and long term.
When you’re ready to take your research to the next level, talk to Worldwide.